In a key leadership transition, Dr. W. Kimryn Rathmell officially began her tenure as the chief executive officer of The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) in May. Dr. Rathmell brings a wealth of experience and nationally recognized expertise in oncology to one of the nation’s leading cancer research and treatment centers.
Before joining OSUCCC – James, Dr. Rathmell served in various academic and clinical roles, including as Chair of the Department of Medicine at Vanderbilt University Medical Center. Her research has primarily focused on the genetic and molecular basis of kidney cancer, and she is known for her contributions to precision medicine.
Rathmell’s appointment is expected to bolster the center’s ongoing mission to provide cutting-edge cancer care while advancing research and education. Leaders at Ohio State University have expressed confidence in her vision and ability to guide the institution to new levels of excellence in both patient care and scientific discovery.
Under Dr. Rathmell’s leadership, OSUCCC – James aims to continue building on its status as one of only a few cancer centers in the nation funded by the National Cancer Institute to conduct both laboratory and patient-centered research. Her strategic initiatives are anticipated to enhance collaboration, expand treatment options, and drive innovation in cancer diagnostics and therapy across the region and beyond.
Source: https:// – Courtesy of the original publisher.
